Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Tandem Diabetes Reports Mixed Q4 Earnings, Issues Better Than Expected FY22 Outlook

Tandem Diabetes Care Inc (NASDAQ:TNDM) reported Q4 sales reached $209.9 million, +25% Y/Y, beating the consensus of $199.12 million.

  • The Company posted EPS of $0.16, down from $0.22 a year ago, and missed the Wall Street estimate of $0.21.
  • Worldwide pump shipments increased 15% Y/Y to 37,585.
  • The gross margin remained almost unchanged at 54%, and the operating margin decreased from 11% to 6%.
  • Tandem Diabetes ended Q3 with cash, cash equivalents, and short-term investments of $595.0 million.
  • Guidance: Tandem forecasts FY22 sales of $845 million - $860 million, representing a Y/Y growth of 20% - 22%, beating the consensus of $827.23 million.
  • The guidance includes sales outside the U.S. of approximately $215 million to $220 million.
  • The gross margin is estimated to be around 54%, with an adjusted EBITDA margin of 14% - 15%.
  • Price Action: TNDM shares traded 2% lower at $104.03 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.